Skip to content
glp1.here

How to get GLP-1 care

Guide

How to get a GLP-1 prescription

By the glp1.here editorial team. Published November 18, 2026. Last reviewed November 18, 2026.

A GLP-1 prescription is a clinician’s order for a specific drug, dose, and patient. It is not a product page, a text-message quiz, or a bottle that arrives because a card was charged. The National Institute of Diabetes and Digestive and Kidney Diseases describes several prescription medicines for overweight and obesity, and it says those medicines do not replace physical activity or healthy eating and that they work best with a lifestyle program. Semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) are among the drugs NIDDK lists for weight management. Each has its own label. This guide is about the path to a prescription. It is not a statement that any one of those drugs is appropriate for you.

Start with the labeled population, not a slogan

Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The same DailyMed label also lists cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and an accelerated-approval indication for noncirrhotic MASH with moderate to advanced liver fibrosis. Those are different uses. A conversation that only says “I want the weight-loss shot” has not yet told the clinician which labeled use is even on the table.

Zepbound’s prescribing information uses a parallel structure for weight reduction in adults with obesity or with overweight plus at least one weight-related comorbid condition, and a separate indication for moderate to severe obstructive sleep apnea in adults with obesity. Saxenda’s label covers adults and pediatric patients 12 years and older with body weight above 60 kg and obesity, and adults with overweight plus at least one weight-related comorbid condition. The labels, not a clinic’s homepage, are the documents that define those populations. Body mass index is a screening measure, not a diagnosis by itself. The NHLBI BMI calculator is a public way to see the arithmetic. Whether the result meets a label is still the prescriber’s call. Read who typically qualifies before you assume a number is enough.

What the visit has to establish

Yale Medicine’s patient explainer on getting started with a GLP-1 describes the practical shape of that first conversation: a history, a discussion of benefits and risks, and a plan that includes food and activity rather than a drug alone. A careful visit, in person or by video, usually has to cover at least the following, because the labels make them relevant.

Personal and family thyroid history. Wegovy, Zepbound, and Saxenda carry boxed warnings that the drugs caused thyroid C-cell tumors in rodents and that it is unknown whether they cause medullary thyroid carcinoma in humans. Each is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. A form that never asks about that history is skipping a boxed warning.

Pregnancy plans. The Wegovy label says the drug may cause fetal harm and, for cardiovascular risk reduction or weight reduction, should be discontinued when pregnancy is recognized. It also says to stop at least two months before a planned pregnancy because of semaglutide’s long half-life. Zepbound’s label says to discontinue when pregnancy is recognized. Those are counseling points, not details to discover after a pen is shipped.

Pancreas, gallbladder, kidneys, and, for people with diabetes, eyes. Labels warn about pancreatitis, gallbladder disease, and acute kidney injury related to dehydration from gastrointestinal side effects. Wegovy’s label discusses diabetic retinopathy in a trial of adults with type 2 diabetes. A history of pancreatitis or gallbladder disease does not automatically forbid treatment, but it is the sort of history a prescriber documents.

Other medicines. The Wegovy label says concomitant use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Zepbound’s label says the same about other tirzepatide products and other GLP-1 receptor agonists. Someone already using Ozempic, Rybelsus, Mounjaro, Trulicity, or Saxenda should say so. Combining them because two programs each sent a box is not a labeled plan.

Diabetes status and glucose-lowering drugs. Labels tell clinicians to monitor glucose when these drugs are used in people with diabetes, and they warn that the risk of hypoglycemia rises when a GLP-1 medicine is used with insulin or a sulfonylurea. The prescriber may need to adjust those other drugs. That is a reason a complete medication list matters.

How the drug will be taken. Wegovy injection is started at 0.25 mg once weekly for four weeks, then escalated on a labeled schedule. Zepbound is started at 2.5 mg once weekly for four weeks, and that 2.5 mg dose is for initiation, not maintenance. Saxenda is started at 0.6 mg daily and increased weekly toward 3 mg. A prescription that begins at a maintenance dose because someone wants faster loss is not the schedule the labels tell prescribers to use to reduce gastrointestinal adverse reactions. The schedules are written out on the semaglutide and tirzepatide references.

In person, by video, or both

The legal and clinical requirement is a licensed prescriber who can evaluate you under the law of the state where you are, not a particular type of furniture. A video visit can collect history, review photos of a scale or a home blood pressure cuff, and order labs. It cannot listen to your abdomen if the clinician thinks an exam is needed, and it cannot see a medicine cabinet you did not mention. An office visit can do those things and can still be rushed. The format is less important than whether the contraindication questions, the medication list, and a follow-up plan exist. What “GLP-1 online” refers to separates the evaluation from the pharmacy shipment that may follow it.

NIDDK notes that weight-management medicines are used with lifestyle treatment. A prescription that arrives with no plan for food, activity, or a return visit is thinner than the labels, which pair the drugs with a reduced-calorie diet and increased physical activity. You can read a practical version of those weeks on GLP-1 Journey.

The prescription is not the fill

After a prescriber sends a prescription, a pharmacy still has to dispense an FDA-approved product or, in narrower circumstances, a compounded drug. Those are not the same thing. FDA has warned that unapproved GLP-1 products, including some compounded semaglutide and tirzepatide, do not get the agency’s premarket review for safety, effectiveness, and quality. Dosing errors with compounded injectable semaglutide have led to adverse events, some requiring hospitalization, according to FDA. A legitimate prescription names a drug and a dose the pharmacy can match to a product. “Semaglutide, whatever is cheapest” is not that.

Insurance adds another gate. Many plans ask for prior authorization before they pay for a weight-management indication, even after a clinician has prescribed. That paperwork is not the same decision as the medical one. The questions plans ask, and what Medicare has published about a time-limited GLP-1 Bridge, are laid out in a prior authorization sheet. Bring your insurance card to the prescribing visit if you hope to use it. If you expect to pay cash, ask which product and which pharmacy path the prescriber will use before you compare prices.

Questions worth asking before you pay anyone

Use the visit, or the message thread after it, to get specific answers.

  • Which labeled product are you prescribing, and for which indication on that label?
  • What is the starting dose and the escalation schedule if I tolerate it?
  • What symptoms should make me stop and call, and what can wait until the next visit?
  • Will you adjust my diabetes medicines if I take any?
  • Where is the prescription being sent, and is that an FDA-approved product?
  • If insurance denies it, what are the cash-pay options you actually work with, and what do they cost this month?
  • When is the follow-up, and what will you look at then?

If the answers are “the pharmacy will explain” or “the dose is whatever the program sends,” pause. Getting GLP-1 online describes what a licensed evaluation includes when the visit itself is remote. Cost and the first weeks separates list prices from self-pay offers and from the slow labeled start.

What this guide cannot do

It cannot tell you that you qualify, that a particular clinic will prescribe, or that you will lose the average amount of weight reported in a trial. STEP 1 and SURMOUNT-1 enrolled selected adults and paired the drugs with lifestyle intervention. Those averages are discussed on the medication reference pages, not as a forecast for your kitchen. Bring the label questions above to a licensed clinician. If you want a telehealth practice that evaluates people for this kind of care, that is a separate choice from reading a guide, and it still has to clear the same history.

Sources

  1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf
  4. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. https://www.yalemedicine.org/news/glp-1-medications-for-weight-loss-how-to-get-started
  6. https://www.nhlbi.nih.gov/calculate-your-bmi
  7. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256